MediciNova
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- -
- Market Cap
- $71.6M
- Introduction
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
MediciNova to Support NIH-Funded Expanded Access Clinical
MediciNova receives $22M NIH grant for EAP to evaluate MN-166 (ibudilast) efficacy in ALS, expanding access to treatment for advanced ALS patients not eligible for COMBAT-ALS trial.
© Copyright 2024. All Rights Reserved by MedPath